We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

AviaraDx CUP Technology Highlighted in Case Study Published in New England Journal of Medicine


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AviaraDx CUP Technology Highlighted in Case Study Published in New England Journal of Medicine "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

AviaraDx, Inc. has announced the publication of a case study, in the September 7th issue of the New England Journal of Medicine, that utilized an assay based upon the company's Molecular Cancer Identification (MCID) technology for the diagnosis of cancer of unknown primary.

The case study was based on a CUP assay developed by a European licensee of AviaraDx.

"We are pleased NEJM has chosen to publish this case study, which provides an example of the benefits that the AviaraDx molecular profiling technology brings to the diagnostic evaluation of these often difficult cases," said Mark Erlander, Ph.D., Chief Scientific Officer of AviaraDx, Inc.

"Correctly identifying the primary tumor origin in CUP patients provides the clinician with options for improved therapy regimens, resulting in better patient prognosis."

Advertisement